The Fort Worth Press - US health regulator rejects MDMA treatment for PTSD, for now

USD -
AED 3.673003
AFN 64.515223
ALL 82.105026
AMD 360.939455
ANG 1.790403
AOA 917.000282
ARS 1564.517498
AUD 1.50215
AWG 1.8
AZN 1.686468
BAM 1.780015
BBD 2.014925
BDT 124.431743
BGN 1.77347
BHD 0.37725
BIF 3005
BMD 1
BND 1.290108
BOB 11.760691
BRL 5.935003
BSD 1.000364
BTN 93.26812
BWP 14.13177
BYN 2.991536
BYR 19600
BZD 2.012105
CAD 1.434375
CDF 2280.000038
CHF 0.84436
CLF 0.0258
CLP 1015.410039
CNY 6.66665
CNH 6.68873
COP 3430.58
CRC 447.852202
CUC 1
CUP 24.010812
CVE 100.775046
CZK 22.275025
DJF 177.719853
DKK 6.81381
DOP 60.203061
DZD 137.16601
EGP 53.810897
ERN 15
ETB 161.293717
EUR 0.91163
FJD 2.308499
FKP 0.76038
GBP 0.764085
GEL 2.595006
GGP 0.76038
GHS 11.774959
GIP 0.76038
GMD 73.999879
GNF 8860.000268
GTQ 7.648344
GYD 209.20879
HKD 7.84275
HNL 27.059762
HRK 6.831965
HTG 131.167832
HUF 340.365019
IDR 18262
ILS 3.298955
IMP 0.76038
INR 93.29525
IQD 1514
IRR 1937314.498435
ISK 125.079589
JEP 0.76038
JMD 158.33375
JOD 0.708986
JPY 159.830498
KES 130.039751
KGS 87.449757
KHR 4074.999893
KMF 449.000068
KPW 900.00035
KRW 1335.290402
KWD 0.31197
KYD 0.833781
KZT 450.420933
LAK 22530.000276
LBP 89550.000037
LKR 332.990535
LRD 167.7498
LSL 17.495007
LTL 2.95274
LVL 0.604889
LYD 6.465018
MAD 9.969502
MDL 18.358468
MGA 4584.999615
MKD 56.115705
MMK 2099.801407
MNT 3600.814049
MOP 8.083819
MRU 40.665013
MUR 46.83996
MVR 15.409893
MWK 1737.000281
MXN 19.08655
MYR 4.113197
MZN 63.910086
NAD 17.494996
NGN 1351.860085
NIO 36.939758
NOK 9.772145
NPR 149.256652
NZD 1.823819
OMR 0.384493
PAB 1.000505
PEN 3.448035
PGK 4.520971
PHP 63.812022
PKR 276.450401
PLN 4.045645
PYG 6272.553936
QAR 3.642975
RON 4.875906
RSD 107.290995
RUB 82.15309
RWF 1477
SAR 3.753475
SBD 8.130619
SCR 13.950753
SDG 601.498401
SEK 10.196615
SGD 1.291896
SHP 0.760572
SLE 22.799754
SLL 20969.503664
SOS 572.502337
SRD 37.359787
STD 20697.981008
STN 22.6
SVC 8.753544
SYP 13002.000337
SZL 17.510247
THB 33.973503
TJS 9.202511
TMT 3.51
TND 3.04875
TOP 2.40776
TRY 50.557098
TTD 6.788623
TWD 33.036986
TZS 2659.997974
UAH 45.068373
UGX 4236.613258
UYU 40.609599
UZS 11994.99959
VES 917.61775
VND 25755
VUV 120.949122
WST 2.823281
XAF 597.990291
XAG 0.023312
XAU 0.000276378611
XCD 2.70255
XCG 1.803049
XDR 0.707052
XOF 597.990291
XPF 109.106681
YER 236.549609
ZAR 17.503203
ZMK 9001.177673
ZMW 20.559821
ZWL 321.999592
SSP 5879.599296
MXV 2.140099
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

US health regulator rejects MDMA treatment for PTSD, for now
US health regulator rejects MDMA treatment for PTSD, for now / Photo: © GETTY IMAGES NORTH AMERICA/AFP

US health regulator rejects MDMA treatment for PTSD, for now

US health regulators on Friday denied an application for treating post-traumatic stress disorder (PTSD) with the drug MDMA, commonly known as ecstasy, saying more investigation needed to be done.

Text size:

The company that submitted the application, Lykos Therapeutics, said in a statement that the Food and Drug Administration (FDA) had requested an additional Phase 3 clinical trial to study MDMA's "safety and efficacy."

A panel of experts convened by the FDA to evaluate clinical data on MDMA had overwhelmingly voted in early June to say there was insufficient evidence to prove it was effective.

While unsurprising, the decision announced Friday represents a blow to advocates of the novel treatment.

"The FDA request for another study is deeply disappointing, not just for all those who dedicated their lives to this pioneering effort, but principally for the millions of Americans with PTSD... who have not seen any new treatment options in over two decades, said Lykos CEO Amy Emerson.

PTSD is a debilitating mental health condition that develops after a person experiences or is threatened by traumatic events such as death, combat or sexual assault.

It affects an estimated five percent of Americans in any given year.

Pharmaceutical treatment options for PTSD are so far limited to two antidepressants that require three months of dosing to take effect, and response rates to the medications have been found to be uneven.

MDMA -- methylenedioxymethamphetamine -- is a Schedule 1 drug under the Controlled Substances Act, and approving it for medical use would have represented a major shift.

California-based Lykos based its request for regulatory approval on two clinical studies, each of which enrolled around 100 people, to evaluate MDMA used together with other psychological interventions such as talk therapy, against a placebo with talk therapy.

These two studies, published in the prestigious journal Nature Medicine, indicated MDMA was indeed both safe and highly effective at treating PTSD.

But nine out of 11 experts on the FDA panel said available data was not enough to show the treatment was effective, and 10 out of 11 said the benefits did not outweigh the risks.

In a briefing document put together ahead of the meeting, FDA staff raised concerns about Lykos's clinical trial methodology and criticized the company for not gathering sufficient side effect data.

The company said it will "work diligently in the coming months to address FDA's concerns and to take advantage of agency processes to resolve scientific disagreements."

"We intend to work tirelessly and use all available regulatory pathways to find a reasonable and expeditious path forward," Emerson added.

L.Holland--TFWP